Enanta Pharmaceuticals Presents Data on a Novel Non-Fusion Inhibitor of Respiratory Syncytial Virus (RSV) at the 10th Annual Respiratory Syncytial Virus Conference
- Lead compound shows promising anti-viral activity in RSV-A and RSV-B
Data presented in a poster titled, EP-023938, A Novel Non-Fusion Replication Inhibitor of Respiratory Syncytial Virus (RSV), M.H. J. Rhodin, et al., demonstrated that EP-023938 is a potent inhibitor of both RSV-A and RSV-B activity, maintaining antiviral activity post-infection while presenting a high barrier to resistance. Further, EP-023938 maintained antiviral potency across all clinical isolates tested as well as virus that was resistant to fusion inhibitors. Given this favorable preclinical profile, along with demonstrated synergy with inhibitors of other mechanisms, Enanta plans to continue evaluation of EP-023938 as a potential development candidate for RSV.
EP-023938 is a non-fusion inhibitor and one of several discovered by Enanta for potential development for RSV. Enanta believes that its approach differentiates its compounds from fusion inhibitors currently in development for RSV because its non-fusion inhibitors directly target the virus replication machinery and have demonstrated high barriers to resistance against the virus in vitro. Additionally, non-fusion inhibitors have the potential of being effective at later stages of infection.
The abstract can be viewed at http://www.rsv16.org/.
About RSV
Respiratory syncytial virus (RSV) is a virus that infects the lungs and represents a serious unmet medical need in infants and children, as well as immune-compromised individuals and the elderly. RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children under 1 year of age in
About Enanta
Enanta has discovered novel protease inhibitors and NS5A inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). Enanta’s protease inhibitors, developed through its collaboration with
Forward Looking Statements Disclaimer
This press release contains forward-looking statements, including statements with respect to the prospects for development of one of Enanta’s lead compounds for the treatment of RSV. Statements that are not historical facts are based on management’s current expectations, estimates, forecasts and projections about Enanta’s business and the industry in which it operates and management’s beliefs and assumptions. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors and risks that may affect actual results include: the development risks of early stage discovery efforts in disease areas such as RSV that have no current therapeutic treatment; potential competition from the development efforts of others in this disease area; Enanta’s lack of clinical development experience; Enanta’s need to attract and retain senior management and key scientific personnel; Enanta’s need to obtain and maintain patent protection for its product candidates and avoid potential infringement of the intellectual property rights of others; and other risk factors described or referred to in “Risk Factors” in Enanta’s most recent Form 10-K for the fiscal year ended
View source version on businesswire.com: http://www.businesswire.com/news/home/20160929006345/en/
Source:
Investor Contact
Enanta Pharmaceuticals, Inc.
Carol Miceli, 617-607-0710
cmiceli@enanta.com
or
Media Contact
MacDougall Biomedical Communications
Kari Watson, 781-235-3060
kwatson@macbiocom.com
- Print Page Print Page
- Email Alerts Email Alerts
- RSS Feeds RSS Feeds
- Contact IR Contact IR